Digital Dose Inhaler Market Outlook 2031
The global digital dose inhaler market size was valued at USD 2.54 Billion in 2022 and is anticipated to reach USD 7.45 Billion by 2031, expanding at a CAGR of 12.7% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing technological advancements and extensive use of smart computing devices.
Digital dose inhalers are devices that help to provide a particular quantity of medication to the lungs and the drug gets self-administered by patients through inhalation. These devices consist of a pressurized canister that helps to release medication into the human body.
Digital dose inhaler also helps patients to track the number of doses consumed as well as control the quantity of the doses digitally due to the built-in sensors. Allergy spray, digihalers, pump or puffer are some alternative names of digital dose inhaler. These devices are utilized in the treatment and medication delivery of respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma.
Digital dose Inhalers reduce medication deposition in throat or mouth and also minimizes the requirement for coordination with actuation of the medical device. It provides access to the user as it can connect through Bluetooth to their mobile phone.
Electronic health records (EHRs) and electronic medical records (EMRs) are parts of digital dose inhaler, which are considered advantage to the modern health information technology. Some of the devices possess advanced features that detect inhaler use and also transmit required data.
Digital Dose Inhaler Market Drivers, Restraints, Trends, and Opportunities
- Growing awareness regarding the benefits of digital dose inhaler market in combination with respiratory medication systems is estimated to boost the market growth.
- Increasing monitoring and management of respiratory diseases are boosting the global digital dose inhalers market growth in coming years.
- Rising predominant factors of respiratory diseases such as COPD and asthma are expected to push the market growth during the forecast period.
- Rising adoption of artificial intelligence (AI) and machine learning (MI) is expected to fuel the market growth.
- High cost of treatments and respiratory inhalers can hinder the market growth.
- Use of digital dose inhaler requires accurate information on various factors, which includes patient compliance and maintenance, and overdose which can restrict the market growth.
Scope of Digital Dose Inhaler Market Report
The report on the global digital dose inhaler market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Digital Dose Inhaler Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI)), Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), and End-users (Hospital and and Clinics)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Glenmark Pharmaceuticals Ltd., AstraZeneca Pl, Novartis International AG, Propeller Health, Philips Respironics, Opko Health, Inc., Teva Pharmaceutical Industries Ltd, Koninklijke Philips N.V., Sensirion AG Switzerland, and H&T Presspart Manufacturing Ltd.
|
Digital Dose Inhaler Market Segment Insights
Type Segment Analysis
Based on types the market is bifurcated into metered dose inhaler (MDI) and dry powder inhaler (DPI). The DPI segment is expected to account for a major market share due to rising occurrence of chronic respiratory diseases, such as COPD and asthma.
Moreover, growing demand for technological attributes of respiratory devices is driving the segment growth. The existence of propellant components, such as chlorofluorocarbons (CFCs) causes drug irritation problems in MDI. This problem is overcome by usage of the DPI, with less irritant impacts.
Applications Segment Analysis
On the basis of applications, the market is segmented into asthma, COPD, and others. The asthma segment is anticipated to expand at a rapid pace during the forecast period owing to rising incidence of respiratory diseases. According to World Health Organization (WHO), around 269 Million people were affected with asthma.
End-users Segment Analysis
In terms of end-users the market is bifurcated into hospital and clinics. The hospital segment is expected to exhibit a high CAGR during forecast period. Patients prefer to visit hospitals due the presence of medical professionals and technology. However, the clinics segment is estimated to expand at a healthy rate owing to the rising number of clinics catering to breathing related ailments.
Regional Outlook
Based on regions, the market is divided into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market share during forecast period due to increasing geriatric population.
Furthermore, the digital dose inhalers market in Asia Pacific is projected to expand at a rapid pace during the forecast period owing to the spread of respiratory diseases, growing urbanization, and increasing pollution and allergens.
Segments
The global digital dose inhaler market has been segmented on the basis of
Types
- Metered Dose Inhaler (MDI)
- Dry powder inhaler (DPI)
Applications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Others
End-Users
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Glenmark Pharmaceuticals Ltd.
- AstraZeneca Pl
- Novartis AG
- Propeller Health
- Philips Respironics
- Opko Health, Inc.
- Teva Pharmaceutical Industries Ltd.
- Koninklijke Philips N.V.
- Sensirion AG Switzerland
- H&T Presspart Manufacturing Ltd.
Competitive Landscape
Key players competing in the digital dose inhaler market include Glenmark Pharmaceuticals Ltd., AstraZeneca Pl, Novartis International AG, Propeller Health, Philips Respironics, Opko Health, Inc., Teva Pharmaceutical Industries Ltd, Koninklijke Philips N.V., Sensirion AG Switzerland, and H&T Presspart Manufacturing Ltd.
Request For Customization
Enquiry Before Buying
Speak With Analyst
